Form 4: NextCure Executive Sourav Kundu Acquires Stock Options

NextCure's Senior VP of Development and Manufacturing, Sourav Kundu, was granted 66,125 stock options on January 31, 2025.

Summary

• Sourav Kundu, Senior VP of Development and Manufacturing at NextCure, Inc., acquired 66,125 employee stock options on January 31, 2025.
• The exercise price of these options is $0.8048 per share.
• One-fourth of the options will vest on January 31, 2026, with the remaining vesting in 36 monthly installments starting February 28, 2026.
• The options expire on January 30, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The granting of stock options to a key executive like Sourav Kundu can be seen as a positive incentive for performance and alignment with shareholder interests.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize key employees and align their interests with the company's long-term success.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in the biotech industry, similar to companies like Amgen, Gilead, and Regeneron.
• The vesting schedule of one-fourth after one year and the remainder over three years is a typical vesting schedule for stock options in the industry.
• The exercise price of $0.8048 is likely based on the current market price of the stock at the time of the grant.

Stakeholder Impact

• The stock option grant could positively impact shareholders by incentivizing the executive to improve company performance.

Key Dates

Keywords

stock options, executive compensation, insider trading, NextCure, NXTC, Sourav Kundu, vesting, equity